Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors.
10.7499/j.issn.1008-8830.2304040
- Author:
Ying CHEN
- Publication Type:Journal Article
- Keywords:
Circulating tumor DNA;
Minimal residual disease;
Solid tumor
- MeSH:
Humans;
Circulating Tumor DNA/genetics*;
Neoplasm, Residual/genetics*;
Biomarkers, Tumor/genetics*;
Neoplasm Recurrence, Local;
Prognosis
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(10):1072-1077
- CountryChina
- Language:Chinese
-
Abstract:
Circulating tumor DNA (ctDNA) is emerging as a novel biomarker for tumor evaluation, offering advantages such as high sensitivity and specificity, minimal invasiveness, and absence of radiation. Currently, various techniques including gene sequencing and PCR are employed for ctDNA detection. The utilization of ctDNA for monitoring minimal residual disease (MRD) enables comprehensive assessment of tumor status and early identification of tumor recurrence, achieving a remarkable detection sensitivity of 0.01%. Therefore, ctDNA holds promise as a biomarker for early diagnosis, treatment response monitoring, and prognosis prediction in solid tumors. This article reviews the commonly used methods for detecting ctDNA and their advantages in evaluating tumor MRD and guiding clinical diagnosis and treatment.
